Altana - Prospects to 2010

Table of Contents

• Principal Operating Results
• Latest Results

EXECUTIVE SUMMARY

• Introduction
  • Current Growth Drivers
  • Key Late-Stage Products
  • Key Early-Stage Products
• Financial Performance 2005
  • Sales and Market Position
  • Income
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure By Geographic Region
    • Capital Expenditure By Business Area
    • R&D Expenditure
    • R&D Expenditure by Business Area
  • Divisional
    • Sales By Business Area
    • Operating Income By Business Area
    • Assets By Business Area
  • Geographic
    • Sales By Destination
    • Assets By Geographic Area
    • Pharmaceutical Sales By Destination
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
    • Discontinued Agreements
    • Pfizer
    • Salix Pharmaceuticals Ltd
      • 22nd August 2005
  • Production
  • Employees
    • Employees By Business Area
• Product / R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
  • Sales Forecasts
• Conclusions

PRODUCT PORTFOLIO / RESE ARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• R&D Pipeline
• Gastrointestinal - Products
  • Major Launched Products
  • Pantozol
    • Sales
  • Pantoprazole Sales By Region
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents
    • Generic Competition/Lawsuits
    • Sales Forecast
• Gastrointestinal - R&D
  • BY424
  • Potassium-competitive acid blocker
  • Soraprazan (BY 359)
• Gastrointestinal - Summary
• Respiratory - Products
  • Major Launched Products
  • Alvesco
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
    • Clinical Trial Results - Paediatric Application
  • Others
• Respiratory - R&D
  • Daxas
    • Clinical Trial Results - COPD
  • Venticute
• Respiratory - Summary
• Other - Products

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005

APPENDIX 2 - KEY AGREE MENTS

• Abbott
• Amersham Health
  • September 1994
• Bayer
• Cyclacel Group plc
  • 16th March 2005
• Evotec AG
  • 25th October 2001
  • 25th March 2002
  • 4th November 2002
  • 6th October 2004
• GPC Biotech AG
  • 8th November 2001
  • May 2002
  • 15th January 2003
  • 12th June 2003
  • 29th October 2003
  • 14th January 2004
  • 23rd December 2004
• Hua Wei
  • 14th July 1998
• Novartis
• Pfizer
• Protherics plc
  • 13th October 1997
  • 31st July and 9th August 1999
• Recordati
  • 2nd January 2002
• Roche
  • 26th January 2001
• sanofi-aventis
  • 15th October 1999
  • 27th March 2001
• Solvay/Fournier Pharma Inc
  • 26th September 2001
• SR Pharma plc
  • 14th May 2002
  • 4th December 2002
  • 16th February 2005
• Tanabe
  • 15th November 2002
• Teijin Limited
  • 13th September 2000
• Wyeth
  • June 1996

APPENDIX 3 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL

• SUBSIDIARIES / JOINT VENTURES
  • Subsidiaries
  • Joint Ventures

APPENDIX 5 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Capital Expenditure By Geographic Region
• Capital Expenditure By Business Area
• R&D Expenditure by Business Area
• Sales By Business Area
• Operating Income By Business Area
• Assets By Business Area
• Sales By Destination
• Assets By Geographic Area
• Pharmaceutical Sales By Destination
• Employees By Business Area
• Recent Product Launches
• Recent Product Approvals
• Key R&D Projects
• Major Products, Therapeutic Areas and Sales
• R&D Pipeline
• Major Launched Products
• Pantoprazole Sales By Region
• Major Launched Products

Index of Charts

• Sales, Costs and Operating Income
• Capital Expenditure By Geographic Region, 2005
• Capital Expenditure By Business Area
• R&D Expenditure by Business Area
• Sales By Business Area, 2005
• Sales By Destination, 2005
• Pharmaceutical Sales By Destination, 2005
• Employees By Business Area
• Sales of Pantozol (2000A-2010E)
• Pantozal Sales (2000A-2010E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity